Latest Breaking News On - Stern investor relations inc - Page 7 : comparemela.com

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90

Courtney mogerleyLesley stanleyStern investor relations incUs food drug administrationAvadel pharmaceuticalsAnnual needham healthcare conferenceInvestor relationsDrug administration

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Janhavi mohiteAnne bowdidgeAdicet bio incStern investor relations incInducement planNasdaq listing ruleAdicet bioInvestor relations

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAlex loboRisvodetinib risvoMiltonh wernerRisvodetinib ikInhibikase therapeutics incDivision of hematologic malignanciesSteam reviewCompany contactStern investor relations incInhibikase or companyExchange commissionTherapeutics reports fourth quarterFull yearHighlights recentAbelson tyrosine kinases

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing.

United statesRisvodetinib ikMiltonh wernerRisvodetinib risvoAlex loboStern investor relations incInhibikase therapeutics incInhibikase or companySteam reviewDivision of hematologic malignanciesCompany contactExchange commissionAbelson tyrosine kinasesChief executive officerUpcoming milestonesHematologic malignancies

Paratus Sciences to Present at 3rd BioCentury-BayHelix East-West Biopharma Summit

NEW YORK and SINGAPORE, Feb. 28, 2024 (GLOBE NEWSWIRE) Paratus Sciences Corporation, a biotechnology company accelerating the discovery of novel therapeutics by leveraging the extraordinary adaptive biology of bats,

Al iskandariyahNew yorkUnited statesTheresa heahAlex loboLiz meloneParatus sciencesParatus sciences corporationBat biology foundationStern investor relations incSingapore paratus sciencesSciences corporationChief executive officerBiocentury bayhelix east west biopharma summitWill asia drive biotechParatus sciences singapore